Marcadores de evolución de la enfermedad inflamatoria intestinal tratada con inmunomoduladores o agentes biológicos / Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents

ResumenEl inicio de un tratamiento inmunosupresor o biológico en un paciente con enfermedad inflamatoria intestinal puede ver modificada la historia natural de su enfermedad; por el contrario, la eficacia no es universal y se pueden acarrear efectos adversos graves.ResumenSe trata de encontrar factores capaces de predecir la respuesta a las diferentes opciones terapéuticas con el fin de poder elegir con mejor criterio la alternativa terapéutica más adecuada a cada paciente. Esto cobraría más importancia aún si el clínico pudiera modificar alguno de estos marcadores de evolución para tener así la posibilidad de cambiar la evolución de la enfermedad del paciente.ResumenSe han estudiado marcadores epidemiológicos, biológicos, clínicos, endoscópicos, radiológicos, genéticos e incluso proteómicos, además de otros relativos a la propia enfermedad o al tratamiento en cuestión. La utilidad real de cada uno de ellos y la evidencia que los sostiene se discuten brevemente en este trabajo(AU)

AbstractImmunosuppressive or biological treatment in patients with inflammatory bowel disease can modify the natural history of their disease, although these treatments are not universally effective and can have severe adverse effects. Attempts have been made to identify predictive factors of response to the various therapeutic options in order to aid the choice of the most appropriate therapeutic alternative in each patient. The possibility of modifying any one of these predictive factors would be of great interest since it would provide the opportunity to alter the course of the disease. Epidemiological, biological, clinical, endoscopic, radiological, genetic and even proteomic markers have been studied, in addition to others related to the disease itself or to specific treatments. The present article briefly discusses the real use of each of these markers and the evidence supporting their utility(AU)

[Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents]. / Marcadores de evolución de la enfermedad inflamatoria intestinal tratada con inmunomoduladores o agentes biológicos.

Immunosuppressive or biological treatment in patients with inflammatory bowel disease can modify the natural history of their disease, although these treatments are not universally effective and can have severe adverse effects. Attempts have been made to identify predictive factors of response to the various therapeutic options in order to aid the choice of the most appropriate therapeutic alternative in each patient. The possibility of modifying any one of these predictive factors would be of great interest since it would provide the opportunity to alter the course of the disease. Epidemiological, biological, clinical, endoscopic, radiological, genetic and even proteomic markers have been studied, in addition to others related to the disease itself or to specific treatments. The present article briefly discusses the real use of each of these markers and the evidence supporting their utility.